Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Ashton Insider Profile
4 Followers
Paul Ashton, President & CEO, Director at EyePoint Pharmaceuticals, holds 457.52K shares in EyePoint Pharmaceuticals (Ticker: EYPT). Most recently, Paul Ashton Bought $10,000 shares of EyePoint Pharmaceuticals on Mar 22, 2016 for an estimated value of 11.30K.
Paul Ashton has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
President & CEO, Director
Roles that Paul Ashton holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 22, 2016 - Mar 22, 2017
Return:-43.00%
The most profitable trade made by Paul Ashton
Paul Ashton's Trading History
List of latest transactions for each holding click on a transaction to see Paul Ashton's performance on stock
You May Also Like
Paul Ashton insider profile FAQ
What is the percentage of profitable transactions made by Paul Ashton?
The percentage of profitable transactions made by Paul Ashton is ―.
What is the average return per transaction made by Paul Ashton?
The average return per transaction made by Paul Ashton is ―.
What stocks does Paul Ashton hold?
Paul Ashton holds: EYPT stocks.
What was Paul Ashton’s latest transaction?
Paul Ashton latest transaction was an Informative Buy of $11.30K.
What was Paul Ashton's most profitable transaction?
Paul Ashton’s most profitable transaction was an Informative Buy of EYPT stock on March 22, 2016. The return on the trade was -43.00%.
What is Paul Ashton's role in EyePoint Pharmaceuticals?
Paul Ashton's role in EyePoint Pharmaceuticals is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.